Podcasts about Gilead

This Special Episode on Atrial Fibrillation covers: Cardiology this Week: A concise summary of recent studies Atrial fibrillation burden: clinical relevance of a new outcome Pulsed field ablation: game changer? Drug treatment following atrial fibrillation ablation Spotlight: Holiday Heart Syndrome Host: Rick Grobbee Guests: Rick Grobbee, Konstantinos Koskinas, Jason Andrade, Arian Sultan, Michiel Rienstra Want to watch that special episode? Go to: https://esc365.escardio.org/event/2549 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Jason Andrade, Yasmina Bououdina, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Michiel Rienstra has declared to have potential conflicts of interest to report: consultancy fees from Bayer (OCEANIC-AF national PI) , InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution. Speaker fee from Daiichi-Sankyo, Pfizer to the institution. Unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017). Unrestricted research grant from the European Union's Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). This research is funded by the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01 -002 -2022 -0118 EmbRACE.  Emma Svennberg has declared to have potential conflicts

The Guilty Feminist 474. Waterstone's Book Club Presented by Deborah Frances-White with special guests Max Olesker and Jess Robinson Recorded 23 February 2026 at Waterstone's Piccadilly. Released 16 March. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Max Olesker https://www.instagram.com/maxolesker https://lnk.to/MakingTheCut https://maxolesker.com More about Jess Robinson https://www.instagram.com/jessrobinsonofficial https://jessrobinson.lnk.to/lifeisrosibook https://www.jessrobinson.co.uk For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Endometriosis Special. 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

There is quite a story to the Spiritual, "There is a Balm in Gilead." Hear the hymn and how it ties to the book of Numbers, Jeremiah and the gospel of John. There is healing to be found in your life!

Send a textWhen Yvette Raphael walked into a stakeholder meeting in Kigali in 2019 and asked Gilead's lead researcher, "What are you going to do differently?", she was doing her job. As co-founder of Advocacy for Prevention of HIV in Africa and chair of the Global Community Advisory Board for the PURPOSE 1 trial, Yvette has spent decades ensuring that women most affected by HIV are not just research subjects, but architects of the science designed to protect them.In this episode, she tells the inside story of lenacapavir, Science magazine's 2024 Breakthrough of the Year, from the community trust-building that made the PURPOSE trials possible, to the moment at AIDS 2024 when results showing 100% efficacy brought a room of scientists to their feet.But Yvette is clear: a breakthrough is only a breakthrough if it reaches the people who need it. With PEPFAR funding under threat and rollout decisions being made without community voices, she pulls no punches on what accountability from science, pharma, and governments must actually look like.To support us, consider becoming a paid subscriber on Patreon or making a one-time donation via PayPal. Subscribe to our weekly newsletter: globalhealthunfiltered.comFollow us on X (@unfiltered_gh), LinkedIn, Instagram, and TikTok.

You keep hearing about AI, but nobody is telling you how it actually fits into a biotech career or a job search. That changes today.In this episode, Carina sits down with Heather Karner, a bench scientist with a background in RNA biology who works alongside machine learning researchers in the Bay Area. Heather is actively job searching and has quietly become the go-to AI resource for her lab and her network, not because she is a tech expert, but because she started experimenting and never stopped.Together they share the exact AI use cases they are running right now: a personalized daily brief that flagged Gilead and Eli Lilly RNA acquisitions before they hit LinkedIn, a literature review workflow built for scientists, how to use AI as a tireless teacher for coding and lab protocols, AI note taking that surfaced 10 action items from a 10-minute meeting, and how to turn a rambling brain dump into a clear, professional message.

The Guilty Feminist 473. Fascism Presented by Deborah Frances-White and Desiree Burch with special guest Professor Roger Griffin Recorded 20 February 2026 at the Museum of Comedy. Released 9 March. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Desiree Burch https://www.instagram.com/destheray https://www.desireeburch.com More about Roger Griffin https://www.brookes.ac.uk/profiles/staff/roger-griffin https://www.amazon.co.uk/Nature-Fascism-Roger-Griffin/dp/1138174084 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live 30 April, Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead 10 April, 17 April, 14 May, 22 May Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 473. Fascism Presented by Deborah Frances-White and Desiree Burch with special guest Professor Roger Griffin Recorded 20 February 2026 at the Museum of Comedy. Released 9 March. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Donate to reproductive freedom, support MSI Reproductive Choices and visit msichoices.org More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Desiree Burch https://www.instagram.com/destheray https://www.desireeburch.com More about Roger Griffin https://www.brookes.ac.uk/profiles/staff/roger-griffin https://www.amazon.co.uk/Nature-Fascism-Roger-Griffin/dp/1138174084 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live 30 April, Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead 10 April, 17 April, 14 May, 22 May Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Sabiha Gati Guest: Thomas F. Luescher Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This teaching is taken from Proverbs 9:10-11 and teaches you about extending your life. If you have any questions, or you would like to share how our teachings have affected your life, please email us or visit us at rejoicingheart.net God bless you! Rob and Donna Rejoice In You From the Integrity Music Release One, featuring Planetshakers Ministries Int'l ©2009 Planetshakers Publishing (APRA) (admin. By Music Services, www.musicservices.org) All Rights Reserved. Used by permission. Proverbs 9:10-11 (KJV) 10 The fear of the LORD is the beginning of wisdom: and the knowledge of the holy is understanding. 11 For by me thy days shall be multiplied, and the years of thy life shall be increased. 1 Kings 3:12 (KJV) 12 Behold, I have done according to thy words: lo, I have given thee a wise and an understanding heart; so that there was none like thee before thee, neither after thee shall any arise like unto thee. Proverbs 1:7 (KJV) 7 The fear of the LORD is the beginning of knowledge: but fools despise wisdom and instruction. Proverbs 4:7 (KJV) 7 Wisdom is the principal thing; therefore get wisdom: and with all thy getting get understanding. Hosea 4:6 (KJV) 6 My people are destroyed for lack of knowledge: because thou hast rejected knowledge, I will also reject thee, that thou shalt be no priest to me: seeing thou hast forgotten the law of thy God, I will also forget thy children. James 1:17 (KJV) 17 Every good gift and every perfect gift is from above, and cometh down from the Father of lights, with whom is no variableness, neither shadow of turning. John 10:10 (KJV) 10 The thief cometh not, but for to steal, and to kill, and to destroy: I am come that they might have life, and that they might have it more abundantly. Psalm 91:16 (KJV) 16 With long life will I satisfy him, and shew him my salvation. Psalm 91:1 (KJV) 1 He that dwelleth in the secret place of the most High shall abide under the shadow of the Almighty. Proverbs 3:7-8 (KJV) 7 Be not wise in thine own eyes: fear the LORD, and depart from evil. 8 It shall be health to thy navel, and marrow to thy bones. Proverbs 4:20-22 (KJV) 20 My son, attend to my words; incline thine ear unto my sayings. 21 Let them not depart from thine eyes; keep them in the midst of thine heart. 22 For they are life unto those that find them, and health to all their flesh. Deuteronomy 34:1 (KJV) 1 And Moses went up from the plains of Moab unto the mountain of Nebo, to the top of Pisgah, that is over against Jericho. And the LORD shewed him all the land of Gilead, unto Dan, Deuteronomy 34:7 (KJV) 7 And Moses was an hundred and twenty years old when he died: his eye was not dim, nor his natural force abated. Proverbs 10:27 (KJV) 27 The fear of the LORD prolongeth days: but the years of the wicked shall be shortened.

On this week's episode, Tess Cameron, Josh Schimmer, Brian Skorney, and special guest Adam Feuerstein kick off with regulatory updates, including the FDA's rejection of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals' cell therapy, Ebvallo -- a therapy that should have been approvable. The co-hosts then highlight ongoing inconsistencies at the agency and the challenge it creates for investors and companies as the regulatory goal posts continue to shift. Next, they discuss a New York Post editorial from the Alliance for Regenerative Medicine CEO Tim Hunt, who outlined how last‑minute reversals on rare disease and CGT approvals are leaving patients and biotech companies in limbo. The conversation then shifts to deals, including Gilead's $7.8B acquisition of Arcellx for full control of anito-cel for relapsed/refractory multiple myeloma, and Vir's pivot to oncology through a $1.7B collaboration with Astellas. In data news, the co-hosts cover CagriSema's head-to-head trial results against Lilly's Zepbound, Gossamer Bio's lung disease drug, seralutinib, which did not meet the primary endpoint in its Phase 3 pulmonary arterial hypertension study, and Palvella Therapeutics' positive topline results from the Phase 3 study of QTORIN rapamycin in microcystic lymphatic malformations. The episode closes with company updates, including Sarepta CEO Doug Ingram's retirement and Xenon Pharmaceuticals' upcoming seizure drug readout. *This episode aired on February 27, 2026.

In the industry news section of this week's episode, we kick things off with Tamarind Bio's efforts to develop user-friendly artificial intelligence tools for science researchers. Then we examine the impact of the U.S. Food and Drug Administration's reversal on its earlier refusal to review Moderna's mRNA vaccine for the flu, discuss Gilead's acquisition of Arcellx to expand its cancer therapy pipeline, and dive into Takeda's investment in Vir Biotech's prostate cancer candidate. Then on the research front, we get into the science behind new protein-like polymers engineered to target and degrade some of cancer's most challenging driver proteins. And we discuss a potential control switch for CAR T cells that could make these immunotherapies much safer. Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for BiologyBy Fay Lin, PhD, GEN Edge, February 24, 2026 StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine CompaniesBy Alex Philippidis, GEN Edge, February 21, 2026Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer PipelineBy Alex Philippidis, GEN Edge, February 23, 2026Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer CollaborationBy Alex Philippidis, GEN, February 26, 2026New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving CancerGEN, February 11, 2026Drug-Controlled CAR T Cells May Enable Safer ImmunotherapyGEN, February 23, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorization process for rare conditions; Another leadership change shakes up CDC; and Gilead acquires CAR T partner Arcellx for nearly $8 billion.  Everything is coming up Lilly. The Indianapolis-based pharma bested its chief rival, Novo Nordisk in a head-to-head test. In a Phase 3 trial initiated by Novo itself, Lilly's Zepbound generated 25.5% weight loss while the Danish pharma's CagriSema elicited 23%. The results sent Novo's shares plummeting by an unprecedented 20% to a pre-Wegovy valuation while Lilly's market cap continues to climb.   Novo attempted a comeback on Tuesday, announcing that its triple-G agonist UBT251 scored almost 20% weight loss after 24 weeks in a Phase 2 trial in China. By comparison, Lilly's own triple-G competitor retatrutide led to 17.5% weight loss over the same timeframe, according to BMO Capital Markets analysts. Novo also sweetened the pot, announcing that it would slash the prices for all three of its GLP-1 medicines starting in 2027.    Meanwhile, the FDA kicked off Rare Disease Week with draft guidance on the new Plausible Mechanism Pathway for personalized therapies that was first teased in November. Jumping off last summer's Baby KJ success story, the new pathway is aimed at advancing treatments for ultra-rare diseases. And a bipartisan senate hearing on Thursday will focus on the authorization process for rare disease therapies.  While the rare disease space has enjoyed recent regulatory progress, funding these vital therapies remains a challenge. Companies like the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech, are trying to change this with creative approaches including tax exempt status and unique partnerships with CDMOs and CMOs. Finally, in a move that also has implication for the rare disease space, the FDA's official pivot from a two clinical trial requirement to just one for new drug applications is lighting up biopharma social media.   And over at the CDC, there is more upheaval on the leadership front as National Institutes of Health Director Jay Bhattacharya replaces acting director Jim O'Neill as head of the agency, and principal deputy director Ralph Abraham steps down, citing “unforeseen family obligations.”    On the business front, Gilead inked the biggest M&A deal of the year so far, acquiring CAR T partner Arcellx for nearly $8B. And Merck's Keytruda should have a few extra years of dominance thanks to a web of patents, with billions on the line. Check it out in BioPharm Executive, in your inboxes Wednesday.  HostsJef Akst, Managing Editor, BioSpaceHeather McKenzie, Senior Editor, BioSpaceAnnalee Armstrong, Senior Editor, BioSpace

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury's analysts assess what the deal does for the Foster City, Calif.-based biotech's pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week's PhRMA Forum, which focused on China and the Trump administration's most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA's about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Enttäuschung bei Novo Nordisk, Gileads Milliarden-Move und Übernahmefantasie bei Paypal. Außerdem geht es um Mongo DB, Zscaler, Datadog Doordash, American Express, Mastercard, Visa, Novo Nordisk, Eli Lilly, Gilead, Arcellx, Domino's, IBM, PayPal, BMW, VW, Mercedes-Benz, SAP, Infineon, Cloudflare, Crowdstrike, Zscaler, KKR, Blackstone, Apollo, GE Vernova, L&G Gold Mining ETF (WKN: A12CCL), L&G DAX Daily 2x Short (WKN: A0X8ZS), Amundi Core MSCI USA (WKN: ETF154), iShares MSCI USA (WKN: A0YEDU), SPDR S&P 500 (WKN: A3EUC1), UBS Core S&P 500 (WKN: A41DL0), SPDR S&P 500 Leaders (WKN: A2PSPE), iShares Core MSCI World (WKN: A0RPWH), Ark Innovation ETF (A14Y8H) und SPDR MSCI All Country World IMI (WKN: A1JJTD). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Wie steht's um deine Altersvorsorge? Kannst du dir jetzt bei Scalable Capital kostenlos ausrechnen: Mehr dazu hier. Zoll-Chaos drückt Märkte, Gold & China steigen. Wintersturm legt Airlines lahm. Software stürzt weiter. PayPal springt nach Übernahmegerücht. Gilead x Arcellx. Novo Nordisk crasht. Enel investiert. Lambo will kein E-Auto. IQM will an Börse. 20% Wachstum pro Jahr mit simplen Rohrverbindern? Reliance Worldwide (WKN: A2AHE7) dominiert mit der Marke SharkBite 85% des US-Marktes und ist das „Tesa“ der Klempner-Branche. 50% Rendite gab's für Südafrikas Leitindex letztes Jahr. Trotz 31% Arbeitslosigkeit. Wir schauen uns an, welche Rolle Player wie Shoprite (WKN: 853202), Capitec (WKN: 779555) oder Remgro (WKN: 578937) dabei spielen. Diesen Podcast vom 24.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

The Guilty Feminist 471. The History of Queerphobia Presented by Deborah Frances-White and Abigoliah Schamaun with special guest Dr Harry Tanner Recorded 13 February 2026 at the Museum of Comedy in London. Released 23 February 2026. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Abigoliah Schamaun https://www.instagram.com/abigoliah https://abigoliah.com https://www.youtube.com/watch?v=rp1GBgUIMG4 https://linktr.ee/ndm_book https://podfollow.com/all-british-comedy-explained More about Dr Harry Tanner https://www.instagram.com https://harryjamestanner.com For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show Waterstone's Book Club, 23 February. https://www.waterstones.com/events/the-guilty-feminist-x-waterstones-book-club-jess-robinson-and-max-olesker/london-piccadilly Zack Polanski and Juno Dawson at The Union Chapel, 5 March. https://www.gigantic.com/the-guilty-feminist-tickets/london-union-chapel/2026-03-05-18-30 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 471. The History of Queerphobia Presented by Deborah Frances-White and Abigoliah Schamaun with special guest Dr Harry Tanner Recorded 13 February 2026 at the Museum of Comedy in London. Released 23 February 2026. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Abigoliah Schamaun https://www.instagram.com/abigoliah https://abigoliah.com https://www.youtube.com/watch?v=rp1GBgUIMG4 https://linktr.ee/ndm_book https://podfollow.com/all-british-comedy-explained More about Dr Harry Tanner https://www.instagram.com https://harryjamestanner.com For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show Waterstone's Book Club, 23 February. https://www.waterstones.com/events/the-guilty-feminist-x-waterstones-book-club-jess-robinson-and-max-olesker/london-piccadilly Zack Polanski and Juno Dawson at The Union Chapel, 5 March. https://www.gigantic.com/the-guilty-feminist-tickets/london-union-chapel/2026-03-05-18-30 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literature

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

In this RTB and Novel Dialogue episode from 2021, Helen Garner sits down with John and Elizabeth McMahon, a distinguished scholar of Australian literature. Helen's novels range from the anti-patriarchy exuberance of Monkey Grip (1977) to the heartbreaking mortality at the heart of The Spare Room (2008). She has also authored a slew of nonfiction, plus screenplays for Jane Campion's Two Friends and Gillian Armstrong's wonderfully Garneresque The Last Days of Chez Nous. After a reading from John's favorite, The Children's Bach, the trio discusses Garner's capacity for cutting and cutting, creating resonant, thought-inducing gaps. Garner connects that taste for excision, perhaps paradoxically, to her tendency to accumulate scraps, bits and pieces of life. She relates her father's restlessness to her own life-total of houses inhabited (27). “Why wouldn't I write about households?” asks Helen, “They're just so endlessly interesting.” Who shaped her writing? Raymond Carver: packed with power, but the pages white with omissions and excisions. Helen offers an anecdote about her own pruning that ends with her “ankle-deep in adverbs.” That's how to escape the “fat writing” that stems for distrust of the reader. She thoughtfully compares the practical virtues of keeping notebooks for the “music” of everyday life to the nightly process of diary-writing (more analytical). John raises the question of pervasive musical metaphors in Helen's writing, and she reports her passion for “boring pieces” and the “formal” side of Bach, which makes a listener feel that there is such a thing as meaning. “There's something about shaping a sentence, too, which can be musical.” Mentioned in the Episode Marilynne Robinson, Housekeeping (the fixed people and the wandering people), Gilead, Home, The West Wing (yes, the TV show! Helen watched it during lockdown when she couldn't bear fiction…) Raymond Carver‘s minimalist fiction (his first collection) Tess Gallagher (as writer and as Carver's editor) Willa Cather, “The Novel Démeublé” (1922; on how to un-furnish fiction, leaving it an empty room) Ernest Hemingway, A Moveable Feast Sigmund Freud on “the day's residue” (e.g. in The Interpretation of Dreams, 1900) George Eliot, Quarry for Middlemarch Listen to Episode Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/australian-and-new-zealand-studies

Audio roundup of selected biopharma industry content from Scrip over the business week ended February 13, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Scrip Asks on R&D Innovation; Bayer's “paradigm-changing” stroke results; AstraZeneca's precision oncology approach; Gilead's CMO reflects on pipeline; and India's pharma chiefs on driving innovation. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-EP6IJB43CRG7XBFEWVVN7V3FXE/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

APAC stocks were mostly higher as the region took impetus from the gains on Wall Street, where the S&P 500 approached closer towards its record levels, and the Nasdaq outperformed as the tech rebound persisted.US President Trump and Chinese President Xi's summit is reportedly set for the first week of April, POLITICO reported, but the White House later clarified that the Trump-Xi meeting has not been finalised.The EU is reportedly readying options to give Ukraine gradual membership rights and is preparing a series of options to embed Ukraine's membership in a future peace deal.UK PM Starmer told Labour MPs that he is "not prepared to walk away" from power or "plunge us into chaos" as previous prime ministers have done.European equity futures indicate a slightly lower cash market open with Euro Stoxx 50 futures down 0.1% after the cash market closed with gains of 1.0% on Monday.Looking ahead, highlights include Norwegian CPI (Jan), US NFIB (Jan), Weekly ADP, ECI (Q4), Retail Sales (Dec) & EIA STEO. Speakers include Fed's Hammack & Logan, Supply from the Netherlands, UK, Germany & US. Earnings from Coca-Cola, S&P, Gilead, Robinhood, Welltower, Duke Energy, Datadog, Ford, AIG, Xylem, Spotify, AstraZeneca, BP, Barclays, Ferrari and Mediobanca.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

European bourses are mostly firmer, US equity futures are flat/incrementally higher.DXY is flat awaiting Retail Sales/ECI, JPY bid alongside JGB stabilisation whilst NOK gains post-inflation.Fixed rebounds from Monday's pressure into data & supply; Gilts outperform as PM Starmer pushed back on calls to resign.WTI and Brent mildly lower, XAU remains above USD 5k/oz; Copper muted heading into Chinese festive period.Looking ahead, highlights include US NFIB (Jan), Weekly ADP, ECI (Q4), Retail Sales (Dec) & EIA STEO. Speakers include Fed's Hammack & Logan, Supply from the US. Earnings from Coca-Cola, S&P, Gilead, Robinhood, Welltower, Datadog, Ford, AIG, Xylem.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA's focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of stories that highlight the scientific advancements, regulatory updates, and strategic maneuvers shaping our industry.Let's begin with Biogen's efforts to breathe new life into its spinal muscular atrophy treatment, Spinraza. In response to declining sales, Biogen is launching a high-dose version in Japan, aiming to enhance therapeutic efficacy and regain market competitiveness. This move underscores the company's strategy to offset projected revenue declines by 2026. The decision to pursue this high-dose version reflects Biogen's commitment to maintaining its foothold in a challenging market landscape where innovation is key to survival.Shifting gears to regulatory news, the FDA, led by Commissioner Marty Makary, has taken a firm stance against the proliferation of illegal copycat drugs. This announcement comes on the heels of Hims & Hers' controversial introduction of a compounded version of Novo Nordisk's obesity drug, Wegovy. The FDA's commitment to protecting intellectual property and patient safety is crucial in an era where health tech firms increasingly challenge traditional pharmaceutical boundaries. Novo Nordisk's aggressive marketing strategy for Wegovy, including a high-profile Super Bowl advertisement, highlights the competitive pressures in this growing market segment and underscores the legal tensions between established pharma giants and emerging tech-driven companies.In an unexpected turn of events, BridgeBio faced a significant setback as Pfizer withdrew its tafamidis patent in Europe. This led to a notable drop in BridgeBio's stock price and raised concerns about earlier generic entries into the ATTR-CM market. Such developments signal potential shifts in market dynamics and pricing strategies that companies must navigate carefully.On the clinical front, Bayer's phase 3 study of asundexian has demonstrated remarkable results—a 26% reduction in stroke risk. This positions Bayer favorably against competitors Bristol Myers Squibb and Johnson & Johnson, setting a new benchmark in the high-stakes anticoagulant market. Innovation continues to be paramount as companies strive for superior clinical outcomes that can significantly impact patient care.Regulatory landscapes are evolving as well, with Gilead's Yescarta receiving clearance for expanded use. These milestones are crucial for broadening therapeutic indications and enhancing patient access, underscoring ongoing efforts to address unmet medical needs while sustaining growth trajectories.Meanwhile, Pfizer-backed Priovant has reported promising mid-stage results for brepocitinib in treating dermatomyositis and other rare skin conditions. As a TYK2/JAK1 inhibitor, brepocitinib exemplifies precision medicine's expanding role in addressing autoimmune disorders through targeted therapies.The IPO scene remains vibrant with Agomab Therapeutics and Spyglass Pharma making substantial entries into Nasdaq, collectively raising $350 million. This influx indicates continued investor confidence in biopharma innovation despite broader economic uncertainties—a testament to the sector's resilience and potential for groundbreaking advancements.Corporate dynamics are also shifting as seen with Moderna's Chief Medical Officer Jacqueline Miller stepping down after a brief tenure. Leadership changes such as these often signal strategic realignments within companies as they adapt to complex regulatory environments and competitive pressures.Summarizing these developments illustrates a dynamic landscape marked by scientific innovation, regulatory vigilance, and strategic marketing initiatives. As companies strive for competitive advantage through new drug formulations and market expansions, they must also navigate legal challenges and regSupport the show

Host: Emer Joyce Guest: Borge Nordestgaard Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Lp(a) and aortic valve stenosis The truth about climate change and heart disease Snapshots Host: Emer Joyce Guests: JP Carpenter, Borge Nordestgaard, Hugh Montgomery, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2548 Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.  Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Hugh Montgomery has declared to have potential conflicts of interest to report: funded and runs the charity-funded non-profit 'Real Zero'. Unpaid co-chair of the UK Health Alliance on Climate Change, Lancet Countdown on Health and Climate Change. Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The December 2025 JW Broadcast features the Gilead graduation ceremony, including talks from King Stephen Lett and Real Estate Investor King Jodi Jedele. Listen in as we discuss how salty all the graduates are and what it means when someone asks you for a fire extinguisher!TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast

Welcome to Day 2787 of Wisdom-Trek. Thank you for joining me. This is Guthrie Chamberlain, Your Guide to Wisdom. Day 2787 – Wisdom Nuggets – Psalm 108:10-13 – Daily Wisdom Wisdom-Trek Podcast Script - Day 2787 Welcome to Wisdom-Trek with Gramps! I am Guthrie Chamberlain, and we are on Day two thousand seven hundred eighty-seven of our Trek. The Purpose of Wisdom-Trek is to create a legacy of wisdom, to seek out discernment and insights, and to boldly grow where few have chosen to grow before. The Title for Today's Wisdom-Trek is: The Divine Stomp – Storming the Gates of the Impossible.   Today, we arrive at the grand finale of our journey through Psalm One Hundred Eight. We are trekking through the final stanza, verses ten through thirteen, in the New Living Translation. In our previous trek, we stood in the War Room of Heaven. We heard the Divine Oracle in verses six through nine, where Yahweh looked at the map of the Middle East and claimed His territory. We heard Him declare, "Gilead is mine... Manasseh is mine... Moab is my washbasin... I will wipe my feet on Edom." It was a breathtaking assertion of ownership. We saw God claiming the hostile nations as His servants—His washpots and His shoe-racks. It was a moment of high theology and divine confidence. But today, the scene shifts from the map on the wall to the mud on the ground. In Psalm One Hundred Eight, verses ten through thirteen, King David takes that divine promise and tries to walk it out in the real world. And he immediately hits a wall—literally. He finds himself standing outside the "fortified city" of Edom. The map says Edom belongs to God. But the reality says Edom is locked up tight behind impregnable walls. This is where the rubber meets the road in our spiritual lives. It is one thing to sing about victory in the sanctuary; it is another thing to secure it on the battlefield. It is one thing to believe God owns the problem; it is another to see Him conquer it. In these final four verses, we will see the transition from Promise to Petition, and finally to Participation. We will learn that the only way to breach the fortified city is to abandon human strategies and rely on the Divine Warrior to do the trampling. So, let us draw our swords one last time and march toward the gate. The first segment is: The Crisis of Geography: The Impregnable City. Psalm One Hundred Eight: verse ten. Who will bring me into the fortified city? Who will bring me to Edom? The psalm moves from God's voice back to David's voice. And David has a logistical problem. God just said in verse nine: "I will wipe my feet on Edom."   David responds: "Okay, Lord. But who is going to get me inside?" "Who will bring me into the fortified city? Who will bring me to Edom?" To understand the weight of this question, we have to look at the geography. The ancient capital of Edom was Bozrah, and later Petra (Sela). Edom was legendary for its natural defenses. It was carved into the red sandstone cliffs. The only way in was through a narrow canyon called the Siq. It was a natural fortress that armies broke themselves against for centuries. It was the "Fortified City" (Ir Mibzar) par excellence. When David

Welcome to Day 2785 of Wisdom-Trek. Thank you for joining me. This is Guthrie Chamberlain, Your Guide to Wisdom. Day 2785 – Wisdom Nuggets – Psalm 108:6-9 – Daily Wisdom Wisdom-Trek Podcast Script - Day 2785 Welcome to Wisdom-Trek with Gramps! I am Guthrie Chamberlain, and we are on Day two thousand seven hundred eighty-five of our Trek. The Purpose of Wisdom-Trek is to create a legacy of wisdom, to seek out discernment and insights, and to boldly grow where few have chosen to grow before. The Title for Today's Wisdom-Trek is: The Divine Cartography – God Claims His Geography. Today, we are back on the trail, continuing our exploration of the "Warrior Poet's Remix," Psalm One Hundred Eight. We are trekking through the middle section, verses six through nine, in the New Living Translation. In our previous trek through the first five verses of this psalm, we heard the sound of a "fixed heart." We watched King David wake the dawn with his lyre and declare that God's love is higher than the heavens. We saw him take an old song of lament (from Psalm Fifty-seven) and remix it into a new anthem of confidence. He ended that section with a cosmic prayer: "Be exalted, O God, above the highest heavens. May your glory shine over all the earth." Today, the scene shifts from the cosmic to the concrete. David moves from singing about the stars to looking at a map. He moves from the "heavens" to the dirt and rock of the Middle East. In verses six through nine, we hear God Himself speak. It is a divine oracle spoken from the Holy Sanctuary. In this oracle, Yahweh acts like a victorious General standing over a map of the ancient Near East. He points to specific territories—Shechem, Succoth, Gilead, Moab, Edom, Philistia—and claims them as His own. He essentially says, "This belongs to Me. And this belongs to Me. And that over there? That is just My washbasin." This is a powerful assertion of Divine Ownership. In the Ancient Israelite worldview, where nations were believed to be owned by their respective gods (Chemosh for Moab, Milcom for Ammon), Yahweh is declaring that He is the Landlord of everything. He is redrawing the borders and reclaiming the inheritance for His people. So, let us stand in the war room and listen to the strategy of the King. The first segment is: The Prayer for Rescue: The Right Hand of Power. Psalm One Hundred Eight: verse six. Now rescue your beloved people. Answer and save us by your power. Before the oracle begins, David offers a short, sharp prayer. This acts as the bridge between the praise of the first five verses and the prophecy that follows. "Now rescue your beloved people. Answer and save us by your power." The literal Hebrew here is quite evocative: "That Your beloved ones may be delivered; Save with Your right hand, and answer me!" First, notice the identity of the people. David calls them "Your beloved people" (yedid-echa). This comes from the same root as the name Jedidiah (which was Solomon's name given by God, meaning "Beloved of Yahweh"). This is crucial for our confidence in prayer. David doesn't appeal to God based on Israel's military strength or their moral perfection. He appeals to God's affection. "Lord, these are the ones You love. Therefore, rescue them." Second, notice the method...

Join Melissa Berry as she welcomes Annie Bond, metastatic breast cancer thriver, advocate, and comedian, to share her first-time experience at SABCS 2025. Together, they explore the moments, conversations, and insights that matter most for metastatic patients and advocates, focusing on advocacy, representation, and the power of patient voices. This episode highlights the urgent need for more data and research in metastatic breast cancer and shows how patient advocacy can drive meaningful change. As part of the "Your Guide to SABCS" series, produced with the Triple Negative Breast Cancer Foundation and TOUCH The Black Breast Cancer Alliance, this episode offers a patient-led perspective on SABCS, demonstrating that the conference is about more than science. It emphasizes advancing metastatic breast cancer research and elevating the voices of those living with the disease. Thank you to BioNtech, Lilly, Gilead, AstraZeneca and Pfizer for making this episode possible.

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Francesca Samsel is crafting a new language for our world. That is, she crosses art, science, and visualization to open new ways of understanding and engaging with the natural world, not just visually but across the sensorial spectrum. She recognizes the inextricably social element to this, too, and her work raises our capacity to collaborate, and in the process, alters our sense of what scientific inquiry is and can (and perhaps needs to) be. Her work as her life are teachers we need for the world we are walking into. Origins Podcast WebsiteFlourishing Commons NewsletterShow Notes:vulnerability (11:30)problem with the 'follow your passion' path (14:20)Ganymede (15:00)what she tells her students (15:50)art-science collaboration (16:00)Santa Fe Institute (21:20)James (Jim) Ahrens (24:00)Craig Tweedie (25:20)visual structure to see the complexity in data (29:00)Isaac Asimov 'that's funny' (30:20)the need for scientific breakthrough (31:20)Lia Halloran - your hand will physically guide you the way to breakthrough (31:30)the only mark that you determine as an artist is the first one (33:00)delivery-oriented society (34:30)"Stewardship of Global Collective Behavior" by Joseph Bak-Coleman et al. (40:00)visual vocabulary work (42:00)Art-Sci-Vis Lab at UT Austin (43:20)flourishing (47:00)Gilead by Marilynne Robinson (51:45)lightning round (48:00)Artist: Jon McCormick (work called "Fifty Sisters")Passion: geoscience and the complexity you find when you walk out of the doorHeart sing: fused glass, ice, and rockScrewed up: obliviousness to colleaguesFind Francesca online:Website UT AustinLogo artwork by Cristina GonzalezMusic by swelo on all streaming platforms or @swelomusic on social media

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

Dr. Tom Curran reflects on scripture passages that will transform your life. Tom shares several insights from Song of Songs chapters 4-6 about how much Jesus loves YOU!You have ravished my heart, my sister, my bride; you have ravished my heart with one glance of your eyes, with one bead of your necklace. (Song of Songs 4: 9)Turn your eyes away from me, for they stir me up. Your hair is like a flock of goats streaming down from Gilead. (Song of Songs 6: 5)

The Guilty Feminist 464. Reform's Ties to the ADF Presented by Deborah Frances-White and Susan Wokoma and special guest Jane Bradley. Recorded 23 November 2025 at The Bill Murray Comedy Club. Released 5 January. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Susan Wokoma https://www.instagram.com/susiewoosie12 https://www.instagram.com/p/DFK7aZDI5Sb More about Jane Bradley https://www.instagram.com/janebradleynyt https://www.nytimes.com/by/jane-bradley For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Open Space Event, 17 January. https://www.eventbrite.co.uk/e/road-to-gilead-open-space-event-tickets-1976897741361 Open Space in Basingstoke. https://www.proteustheatre.com/events/open-space-the-road-to-gilead/ Museum of Comedy, 13 February, 20 February, 5 March. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 464. Reform's Ties to the ADF - revisited Presented by Deborah Frances-White and Susan Wokoma with special guests Jane Bradley and Elizabeth Dias. Recorded 9 December 2025 via Riverside. Released 5 January. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Susan Wokoma https://www.instagram.com/susiewoosie12 https://www.instagram.com/p/DFK7aZDI5Sb More about Jane Bradley https://www.instagram.com/janebradleynyt https://www.nytimes.com/by/jane-bradley More about Elizabeth Dias https://www.instagram.com/elizabethjdias https://www.nytimes.com/by/elizabeth-dias For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Open Space Event, 17 January. https://www.eventbrite.co.uk/e/road-to-gilead-open-space-event-tickets-1976897741361 Open Space in Basingstoke. https://www.proteustheatre.com/events/open-space-the-road-to-gilead/ Museum of Comedy, 13 February, 20 February, 5 March. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Word of the Day with Rene Holaday for Monday, 1-5-26: Micah 7:1-20: "Sorrow for Israel's Sins, and God will Forgive Israel." Verse18 says: "He does not retain His anger forever, because He delights in mercy." Verse 14 describes "Shepherd Your people with Your staff.  the flock of Your heritage who dwell solitarily in a woodland, in the midst of Carmel; Let them feed in Bashan and Gilead, as in the days of old." We are watching the full restoration of Israel right now, just as Micah predicts here in this chapter.  Join me this morning to hear how God is a covenant God who keeps His promises and covenants.  He punished Israel for crucifying The Messiah, but He is also their redeemer who brings them back and restores them to the fullest because He delights in MERCY!  ;()  Hurray!! If any of you can help me with firewood, I could use help!  If you're blessed by this daily Bible Study and you can help me with a donation of $5 or more to my PayPal address, it certainly would be appreciated!  This next couple weeks I will be having a "FIREWOOD funds drive" so I can buy more firewood, and you can donate any amount to : reneholaday@gmail.com if you go to PayPal.com and let them know your amount and my PayPal email address.  THANK YOU ahead of time! Blessings to everyone!  ;()

Dr. Rossi interviews a long-time friend and physician about "The Balm of Gilead" and her ministry of physical and spiritual healing in the medical field.

Margaret Atwood is a Canadian writer. She has published more than sixty books spanning novels, poetry, short stories, non-fiction, children's literature, and graphic novels, and has been called “one of the sharpest and most imaginative novelists writing in English”. She is one of only four writers to have won the Booker Prize twice: for The Blind Assassin in 2000 and for her 2019 follow-up to The Handmaid's Tale, The Testaments.Margaret was born in Ottawa in November 1939, shortly after the outbreak of World War II, the second of three children to Carl Atwood, an entomologist. During her early life, she would spend the warmer months in the remote forests of northern Quebec and Ontario where her father tracked insect infestations, and the winters in the city (first Ottawa, later Toronto). She didn't attend school for a full year until the age of twelve.Her childhood scribblings – a “novel” about an ant called Annie, a volume of rhyming poems about cats, and a play about a giant – turned into a more serious ambition to become a writer when Margaret was sixteen. After studying English at the University of Toronto, where she began publishing poems in the college magazine, her first novel, The Edible Woman, came out in 1969, following five collections of poetry. Her most famous work, The Handmaid's Tale, was published in 1985 and depicted a dystopian vision of the United States as a patriarchal and totalitarian place called Gilead. Although it was written during the Reagan era, it has become eerily relevant again in the wake of the election of Donald Trump. Margaret lost her life partner, the writer Graeme Gibson, in 2019. She lives in Toronto.DISC ONE: Anchors Aweigh - US Navy Band DISC TWO: Hearts of Stone - The Charms DISC THREE: Offenbach: Les contes d'Hoffmann, Giulietta Act: Barcarolle. Belle nuit, ô nuit d'amour. Performed by Joan Sutherland (soprano) Huguette Tourangeau (soprano), Plácido Domingo (tenor), Andre Neury (bass), Pro Arte Choir, Lausanne, Choeur Du Brassus, Choeur de la Radio Suisse Romande, Orchestre de la Suisse Romande, conducted by Richard Bonynge DISC FOUR: Four Strong Winds - Ian & Sylvia DISC FIVE: Barrett's Privateers - Stan Rogers DISC SIX: The Handmaid's Tale, Act I Scene 6: The Doctor. Composed by Poul Ruders and performed by Marianne Rorholm, Hanne Fischer (Mezzo-sopranos), Royal Danish Opera Chorus and Royal Danish Orchestra, conducted by Michael Schønwandt DISC SEVEN: We Praise the Tiny Perfect Moles - Orville Stoeber DISC EIGHT: Symphony No. 6 in F Major, Op. 68 "Pastoral": II. Scene am Bach. Andante molto moto. Composed by Beethoven and performed by Philharmonia Orchestra, conducted by Otto Klemperer BOOK CHOICE: How to Survive on a Desert Island by Samantha Bell LUXURY ITEM: A knife and matchbox CASTAWAY'S FAVOURITE: Hearts of Stone - The Charms Presenter: Lauren Laverne Producer: Sarah Taylor

The Guilty Feminist 461. Homophobia and How to Fight It Presented by Deborah Frances-White and Jessica Fostkew with special guest Russell T Davies Recorded 6 December 2025 at Soho Theatre. Released 15 December. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Jessica Fostekew https://www.instagram.com/jessicafostekew More about Russell T Davies https://www.instagram.com/russelltdavies63 https://www.bbc.co.uk/programmes/m002dr53 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Open Space Event, 17 January. https://www.eventbrite.co.uk/e/road-to-gilead-open-space-event-tickets-1976897741361 Museum of Comedy, 13 February, 20 February, 5 March. https://www.museumofcomedy.com/the-guilty-feminist Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 460. Making Our Voices Heard Presented by Deborah Frances-White and Jessica Fostkew with special guests Baroness Barker and Monica Ferro Recorded 16 November 2025 at The Museum of Comedy. Released 8 December. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Amnesty International is the world's largest grassroots human rights organisation, working tirelessly to expose human rights abuses, hold power to account, and campaign for a fairer, safer world. We stand stronger together. Join the Amnesty International community and support their work exposing truth, debunking narratives, confronting perpetrators, defending truth-tellers and equipping communities with evidence to demand change: https://donate.giveasyoulive.com/campaign/amnesty-guilty-feminist-november-2025 More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Jessica Fostekew https://www.instagram.com/jessicafostekew More about Baroness Liz Barker https://members.parliament.uk/member/2501/contact https://www.instagram.com/p/DGQqvX3i7ZE More about Monica Ferro https://www.instagram.com/monicaferrounfpa To fight for change, we need you. Donate today and power us into 2026. https://ayzqzzms.donorsupport.co/page/buildhope For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Museum of Comedy: Friday 13 Feb, Friday 20 Feb, Thursday 5 March. Tickets on sale soon. Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 459. Christian Nationalism Presented by Deborah Frances-White and Felicity Ward with special guests Minnie Rahman and Lucy Winkett Recorded 10 November 2025 at The Pleasance London. Released 1 December. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Amnesty International is the world's largest grassroots human rights organisation, working tirelessly to expose human rights abuses, hold power to account, and campaign for a fairer, safer world. We stand stronger together. Join the Amnesty International community and support their work exposing truth, debunking narratives, confronting perpetrators, defending truth-tellers and equipping communities with evidence to demand change: https://donate.giveasyoulive.com/campaign/amnesty-guilty-feminist-november-2025 More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Felicity Ward https://www.instagram.com/felicityward https://www.felicityward.com More about Lucy Winkett https://www.sjp.org.uk/whos-who/lucy-winkett More about Minnie Rahman https://bsky.app/profile/minnierahman.bsky.social To fight for change, we need you. Donate today and power us into 2026. https://ayzqzzms.donorsupport.co/page/buildhope For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Russell T Davies at Soho Theatre https://sohotheatre.com/events/the-guilty-feminist-9/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of The AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices